Mesoblast Limited reported its fourth‑quarter 2025 financial results, posting net revenue of $30 million—an increase of 74% year‑over‑year—on top of gross sales of $35 million for its flagship cell‑therapy product Ryoncil. The 60% quarter‑over‑quarter rise in gross sales reflects a rapid uptake of the therapy in the pediatric steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD) market, where the company has secured 32 transplant centers for product use.
Ryoncil’s commercial momentum is underscored by the expansion of its distribution network. The company reported that the therapy is now being administered at 32 transplant centers, a number that represents a significant scaling of its commercial footprint since the product’s U.S. launch in March 2025. The broadened adoption has driven the strong revenue growth and supports Mesoblast’s strategy of expanding the product’s indication to adult SR‑aGvHD, a market three times larger than the pediatric segment.
Operating cash burn for the quarter was $16 million, a sharp decline from the $?? previous‑quarter figure and a reflection of the company’s disciplined capital allocation. The reduction in cash outflow is attributable to the company’s focus on scaling Ryoncil sales while maintaining tight control over operating expenses, even as it invests in commercial infrastructure and pipeline development.
CEO Dr. Silviu Itescu highlighted the dual impact of the results, noting that “the quarter was highlighted by continued strong Ryoncil sales and the establishment of a new lower‑cost non‑dilutive financing facility, both of which enable greater flexibility for strategic partnerships and pursuit of label expansion for Ryoncil.” He added that the company’s strong balance sheet and growing sales momentum position it well for future growth.
Analysts have taken note of the robust performance, citing the company’s ability to accelerate Ryoncil adoption and the successful execution of its commercial strategy. The results reinforce confidence in Mesoblast’s ability to generate sustainable revenue growth while maintaining a healthy cash position.
The earnings release also confirmed that Mesoblast secured a new $125 million non‑dilutive credit line at an 8.00% interest rate, of which $75 million has already been drawn. The lower‑cost financing improves liquidity and provides a buffer for continued investment in the adult SR‑aGvHD program and other pipeline candidates, positioning the company for long‑term value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.